Pre-IPO Shanghai Bio-Heart Biological Technology - Conservative About the Outlook
91 Views03 Nov 2021 09:05
The insight mainly analyzed Bio-heart Biological Technology in terms of the industry characteristics, the policy impact, the business of core products (BRS & RDN) and other concerns and uncertainties.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (May.12) - Three Globalization Strategies, GLP-1/Weight Loss Drug, Bio-Heart14 May 2023
- China Healthcare Weekly (Oct28)-OK Lens VBP, Time Required for Biotech to Make Profit, World Changes30 Oct 2022
- Shanghai Bio-Heart Biological Technology (2185.HK) - The Bubble Will Eventually Burst26 Oct 2022
- Pre-IPO Shanghai Bio-Heart Biological Technology - Conservative About the Outlook03 Nov 2021
- Pre-IPO Infervision Medical Technology - Insights on Industry, Business and Concerns30 Sep 2021
- Pre-IPO Shanghai Hanyu Medical Technology - Insights on the Industry and the Products08 Jun 2021
- Pre-IPO Shanghai Bio-Heart Biological Technology - Here Are the Strength and Concerns07 Apr 2021
x